The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


cgb by the numbers
More From The Market Online

Pro Medicus signs $25M contract with US-based Valley Health

Pro Medicus' US subsidiary Visage Imaging has signed a seven-year, $25 million contract with Valley Health…

Pro Medicus posts 130% profit surge as forward contract book hits $1.34b

Pro Medicus posts a 130.3% rise in FY26 NPAT to $265.3m as revenue reaches $261.7m and…
Mesoblast research conept

Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches

Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low…

AVITA Medical raises 2026 outlook after record second quarter

AVITA Medical has raised its 2026 revenue guidance after delivering record quarterly revenue, while forecasting cash…